What is the current Bruker Corporation (BRKR) stock price?

Bruker Corporation is currently trading at $54.23, a change of -1.72% from the previous close. The 52-week range spans from $28.53 to $64.54.

What is the analyst consensus on Bruker Corporation?

12 analysts rate Bruker Corporation as Buy on average. The mean price target is $53.25, implying -1.8% from the current price.

Does Bruker Corporation pay a dividend?

Yes, Bruker Corporation pays an annual dividend with a yield of 0.37% (payout ratio: 38.46%).

Where can I buy Bruker Corporation stock?

You can buy Bruker Corporation (BRKR) at any regulated online broker. Compare the best options (Trade Republic, Scalable Capital, Interactive Brokers, DEGIRO) in our broker comparison by fees, savings plans, and available exchanges.

← Back to Screener

Sector: Healthcare

Open in Terminal → BRKRLive chart · Key metrics · News · Smart money

Bruker Corporation

BRKR Mid Cap

Healthcare · Medical Devices

Updated: Jun 14, 2026, 22:19 UTC

$54.23

-1.72% today

52W: $28.53 – $64.54

52W Low: $28.53 Position: 71.4% 52W High: $64.54

🔗 Compare Brokers

Price Chart

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

22.26x

Forward Price/Earnings

P/S Ratio

2.39x

Price-to-Sales

EV/EBITDA

20.22x

Enterprise Value/EBITDA

Div. Yield

0.37%

Annual dividend yield

Market Cap

$8.3B

Market Capitalization

Revenue Growth

2.7%

YoY Revenue Growth

Profit Margin

-0.34%

Net profit margin

ROE

-0.43%

Return on Equity

Beta

1.3

Market sensitivity

Short Interest

17.41%

% of float sold short

Avg. Volume

2,409,157

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

12 analysts

Avg. Price Target

$53.25

-1.81% upside

Target Range

$35.00 – $69.00

About the Company

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR tech

Sector: Healthcare Industry: Medical Devices Country: United States Employees: 11,085 Exchange: NMS

Bruker Corporation Stock at a Glance

Bruker Corporation (BRKR) is currently trading at $54.23 with a market capitalization of $8.3B. The 52-week range spans from $28.53 to $64.54; the current price is 16% below the yearly high. Year-over-year revenue growth stands at +2.7%.

💰 Dividend

Bruker Corporation pays an annual dividend of $0.20 per share, representing a yield of 0.37%. The payout ratio stands at 38.46%.

📊 Analyst Rating

12 analysts rate Bruker Corporation (BRKR) on consensus: Buy. The average price target is $53.25, implying -1.81% from the current price. Analyst price targets range from $35.00 to $69.00.

Bruker Corporation: The Investment Case in Detail

Bruker Corporation (BRKR) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue growth has slowed to just 2.7%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 17.41% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.